Sabitlenmiş Tweet
We’re excited to share that Cyclarity recently presented Phase 1 clinical trial results for UDP-003 at the AHA Vascular Discovery Scientific Sessions, presented by our VP of Biology, Daniel Clemens.
This is a pivotal milestone not only for our team, but also toward moving cardiovascular treatments from slowing the progression of damage to achieving true plaque reversal. The data offer the first clinical evidence that 7-ketocholesterol, the root cause of atherosclerosis, can be safely targeted and removed from the human body.
Co-CEO Matthew O’Connor shared, “Maintaining cardiovascular health is one of the most powerful levers for extending both lifespan and healthspan, given its central role in slowing systemic aging and preserving brain, kidney, muscle, and metabolic function. Yet directly targeting 7KC—a key driver of plaque buildup—without disrupting essential biological processes has remained a critical and unsolved challenge in medicine. By demonstrating it is possible to precisely bind to and safely excrete this toxic byproduct without disrupting the systems the body depends on, we look forward to furthering our work to bring forward treatments that save millions of lives and fundamentally change the trajectory of how we age."
Results of the phase 1 trial met and exceeded primary, secondary, and exploratory endpoints, evaluating the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of UDP-003, and demonstrating target engagement. This indicates the potential for a paradigm shift in how we treat cardiovascular disease - a future in which the world’s biggest killer is reversible.
To learn more, check out our press release: globenewswire.com/news-release/2…
English
